Condition
Stargardt Macular Degeneration
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06942572Phase 1Recruiting
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT04239625Phase 2Active Not Recruiting
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
NCT02402660Phase 2Enrolling By Invitation
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Showing all 3 trials